1 文献来源rnYounes A,Sehn L H,Johnson P,et al. Randomized phase Ⅲ trial of Ibrutinib and Rituximab plus Cyclophosphamide,Doxorubicin,Vincristine,and Prednisone
1 文献来源rnBachy E, Seymour J F,Feugier P, et al. Sustained progression - free survival benefit of Rituximab maintenance in patients with follicular lymphoma:L